Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study

被引:6
|
作者
Li, Rui [1 ]
Lu, Danli [1 ]
Li, Hao [2 ]
Wang, Yuge [1 ]
Shu, Yaqing [1 ]
Chang, Yanyu [1 ]
Sun, Xiaobo [1 ]
Lu, Zhengqi [1 ]
Qiu, Wei [1 ,3 ]
Yang, Zhi [2 ]
机构
[1] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 3, Guangzhou, Peoples R China
[2] Maoming Peoples Hosp, Dept Neurol, 101 Weimin Rd, Maoming, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Neurol, Multiple Sclerosis Ctr, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuromyelitis optica spectrum disorders; Vomiting; Area postrema; Clinical outcomes; AQP4 antibody titers;
D O I
10.1186/s12883-021-02059-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Early stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, the clinical characteristics and long-term outcomes of these patients remain unknown. We sought to analyze the clinical characteristics, imaging features, and long-term outcomes of NMOSD with non-opticospinal manifestations as initial symptoms. Methods We retrospectively included relevant patients from our center. Clinical, demographic, magnetic resonance imaging, treatment, and outcome data were compared according to the non-opticospinal vs. opticospinal initial symptoms. Results We identified 43 (9.13 %) patients with non-opticospinal initial symptoms among 471 patients with NMOSD. Of these, 88.37 % developed optic neuritis/myelitis during an average follow-up period of 6.33 years. All the non-opticospinal symptoms were brain/brainstem symptoms. Most of the symptoms and associated brain lesions were reversible. These patients had a younger onset age (P < 0.001), lower serum aquaporin-4 (AQP4) antibody titers (P = 0.030), and a lower Expanded Disability Status Scale (EDSS) score at onset (P < 0.001) and follow-up (P = 0.041) than NMOSD patients with opticospinal initial symptoms. In addition, EDSS scores reached 3.0 (indicating moderate disability) later than in patients with opticospinal initial symptoms (P = 0.028). Conclusions Patients with NMOSD with non-opticospinal initial symptoms have a younger onset age, lower serum AQP4 antibody titers, and better clinical outcomes.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders
    Liu, Hanchen
    Zhang, Xianxing
    Chen, Wei
    Xu, Yiwen
    Lin, Xiaoting
    Lin, Aiyu
    NEUROLOGICAL SCIENCES, 2024, 45 (02) : 699 - 707
  • [42] Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study
    Wang, Jingqi
    Cui, Chunping
    Lu, Yaxin
    Chang, Yanyu
    Wang, Yuge
    Li, Rui
    Shan, Yilong
    Sun, Xiaobo
    Long, Youming
    Wang, Honghao
    Wang, Zhanhang
    Lee, Michael
    He, Shane
    Lu, Zhengqi
    Qiu, Wei
    Tan, Sha
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] A 28-year observational study of disease activities in a Japanese cohort of neuromyelitis optica spectrum disorders
    Saji, E.
    Nakajima, A.
    Wakasugi, T.
    Yanagimura, F.
    Yanagawa, K.
    Hokari, M.
    Nshizawa, M.
    Onodera, O.
    Kawachi, I.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 141 - 142
  • [44] Non-immune system comorbidity in neuromyelitis optica spectrum disorders
    Cai, Linjun
    Chen, Hongxi
    Shi, Ziyan
    Wang, Xiaofei
    Du, Qin
    Zhang, Ying
    Lang, Yanling
    Kong, Lingyao
    Luo, Wenqin
    Mou, Zichao
    Lin, Xue
    Zhou, Hongyu
    JOURNAL OF CLINICAL NEUROSCIENCE, 2023, 107 : 16 - 22
  • [45] Relapse and Non-Relapse Hospitalizations in Neuromyelitis Optica Spectrum Disorders
    Narasimhan, Sathya
    Pua, Danielle Kei
    Holroyd, Kathryn
    Mateen, Farrah
    Levy, Michael
    Bhattacharyya, Shamik
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 404 - 404
  • [46] Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum Disorder With Long-Term Remission
    Seok, Jin Myoung
    Park, Min Su
    JOURNAL OF CLINICAL NEUROLOGY, 2021, 17 (04): : 599 - 601
  • [47] Long-term efficacy and safety of eculizumab in aqp4+neuromyelitis optica spectrum disorder
    Wingerchuk, D.
    Berthele, A.
    Fujihara, K.
    Oreja-Guevara, C.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Palace, J.
    Shang, S.
    Yountz, M.
    Miller, L.
    Pittock, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 465 - 465
  • [48] Long-term Efficacy and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
    Barreras, P.
    Vasileiou, E.
    Filippatou, A.
    Fitzgerald, K.
    Levy, M.
    Mowry, E. M.
    Calabresi, P.
    Sotirchos, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 145 - 146
  • [49] Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
    Barreras, Paula
    Vasileiou, Eleni S.
    Filippatou, Angeliki G.
    Fitzgerald, Kathryn C.
    Levy, Michael
    Pardo, Carlos A.
    Newsome, Scott D.
    Mowry, Ellen M.
    Calabresi, Peter A.
    Sotirchos, Elias S.
    NEUROLOGY, 2022, 99 (22) : E2504 - E2516
  • [50] Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
    Yamamura, Takashi
    Weinshenker, Brian
    Yeaman, Michael R.
    De Seze, Jerome
    Patti, Francesco
    Lobo, Patricia
    Von Buedingen, H-Christian
    Kou, Xiujing
    Weber, Kristina
    Greenberg, Benjamin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 66